On September 13, the Department of Health and Human Services (HHS) changed the distribution process for monoclonal antibodies (mAb) therapeutics. The New York State Department of Health (DOH) will now determine how much product each provider receives based on the supply allotted to the State from HHS. The statewide allocation from HHS will be based on COVID-19 case burden and mAb therapeutic utilization. Providers will make direct requests to DOH.
The mAbs therapeutics affected by the new ordering process are:
- Bamlanivimab/etesevimab (Lilly)
- Etesevimab (Lilly – to pair with bamlanivimab already on hand)
- Casirivimab/imdevimab, i.e., REGEN-COV (Regeneron)
DOH has issued guidance (attached) on how to request mAbs. Please note that orders placed before September 14 do not have to be resubmitted to DOH, as they are already in review. All other requests for the week of September 20 should be submitted per DOH’s detailed instructions prior to 5:00 p.m. on Monday, September 20, to COVID19therapeutics@health.ny.gov. These requests will be reviewed that same week and entered in the AmerisourceBergen portal by the Friday deadline for each weekly cycle.
The distribution of mAbs will remain with AmerisourceBergen. DOH will inform AmerisourceBergen of each provider’s request and how much of the request should be filled. The State will be allotted a finite amount of mAb product each week, so providers may not receive the total amount of product they requested.
Only providers that have an active account with AmerisourceBergen can submit requests for the above mAbs at this time. To receive mAb product, providers must continue to report their weekly utilization data to the Federal government through the appropriate system of HHSProtect, TeleTracking or NHSN, depending on facility type. These reports continue to be due every Wednesday. DOH is developing a process to enroll additional qualified providers. More information will be forthcoming in a separate announcement.